Healthcare systems around the world are still primarily designed to treat disease rather than prevent it. Patients navigate a fragmented landscape of providers, diagnostics, specialists, and digital health tools, often without a comprehensive view of their health. At the same time, healthcare costs continue to rise, while chronic diseases place increasing pressure on healthcare systems globally.

Advances in diagnostics, wearable devices, and AI are creating the foundation for a preventative turn in healthcare. One where healthcare becomes more proactive, personalized, and continuous. Instead of intervening once illness occurs, healthcare providers can increasingly help individuals identify risks earlier, make informed decisions, and improve long-term health outcomes.

This is the opportunity Everlab is pursuing.

We are excited to share that our portfolio company Everlab has raised an oversubscribed AUD 65m Series A round led by Airtree Ventures, with participation from Plural, Left Lane Capital, b2venture, and other investors.

Founded in Melbourne in 2023, Everlab is building what it describes as an operating system for human health. The platform combines diagnostics, clinician-led care, specialist access, prescriptions, wearable data, and AI-powered health insights into a single experience. By connecting previously fragmented healthcare data, Everlab helps individuals better understand their health, detect risks earlier, and take action before conditions develop into more serious diseases.

The company's progress highlights the growing demand for preventative healthcare. Since its founding in 2023, Everlab has completed more than 40,000 consultations for over 20,000 individual patients. In addition, the company supports leading organizations including Boston Consulting Group, BHP, and Bain & Company through its preventative healthcare programs.

Having processed more than 21 million biomarker test results, Everlab has generated a unique longitudinal health dataset while delivering meaningful outcomes for patients. Notably, more than 25% of members have received findings that had not previously been identified through the existing healthcare system.

Today, the platform integrates with more than 1,850 healthcare provider locations, works with over 180 clinicians, connects with more than 30 wearable devices, and processes over 200,000 health reports every month.

"Preventative healthcare has long been discussed as the future of medicine, but access to high-quality preventative care remains limited for most people," says Jan-Hendrik Bürk, Partner at b2venture. "Everlab is changing that by combining diagnostics, clinical expertise, and technology into a model that is both scalable and accessible. The team's execution over the past three years has been exceptional, and we are excited to continue supporting them on their journey."

Many of the reasons we invested in Everlab remain as relevant today as they were in 2023. We continue to see a growing focus on prevention, increasing adoption of health technologies, and a greater willingness among consumers to take ownership of their long-term health. Everlab is well positioned at the intersection of these trends.

With this new funding, the company plans to strengthen its clinical and technology infrastructure while accelerating international expansion, beginning with the United Kingdom.

We congratulate Marc, Steven, Anshul, Sam, and the entire Everlab team on this milestone and look forward to supporting them as they continue to make preventative healthcare more accessible to people around the world.